Leukemia
ASCO 2023: International Cooperation and Pediatric Leukemia Outcomes
You're currently viewing OncGenius as a guest. To save your results, create an account or log in.
Advertisement
ASCO 2023: International Cooperation and Pediatric Leukemia Outcomes
NCCN Guidelines: Acute Myeloid Leukemia, Version 3.2023, Focus on BPDCN
Blinatumomab Plus Interfant-06 Chemotherapy in Infants With KMT2A-Rearranged ALL
Poverty’s Impact on Outcomes in Pediatric Acute Lymphoblastic Leukemia
Determining Risk of Relapse After Bone Marrow Transplant Among Patients With AML
Ethnic Disparities in Pediatric Leukemia Survival and U.S./Mexico Border Residence
Is Childhood Leukemia Linked to Maternal Infection During Pregnancy?
Ponatinib vs Imatinib for Newly Diagnosed Patients With Ph-Positive ALL
Food Insecurity and Receipt of SNAP Benefits Among Pediatric Patients With ALL
ASH 2022: Zanubrutinib in Patients With Relapsed or Refractory CLL/SLL
ASH 2022: Efficacy of Triplet Combinations in Acute Myeloid Leukemia
ASH 2022: Impact of Momelotinib on Patient-Reported Quality of Life for Patients With Myelofibrosis
Real-World Cost of Pediatric ALL Care Among Commercially Insured Patients
Dosing of Tisagenlecleucel Among Pediatric Patients With Leukemia and Improved Outcomes
Acute Leukemia Survival Outcomes Over Time in South Australia
Phase III Trial Evaluates Quizartinib for FLT3-ITD–Positive AML
Zanubrutinib for Untreated Patients With CLL/SLL: SEQUOIA Trial
ASCO 2022: Asciminib vs Bosutinib in Pretreated Patients With CML in Chronic Phase
ASCO 2022: Crenolanib Combined With Chemotherapy in Newly Diagnosed FLT3-Mutant AML
ASCO 2022: New Data on IDH2-Mutant Alleles and Endasidenib in AML
ASCO 2022: Measurable Residual Disease Testing as Prognostic Tool in Acute Myeloid Leukemia
Addition of Ivosidenib to Azacitidine in Newly Diagnosed IDH1-Mutated AML